Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Bortezomib in Relapsed/Refractory PTCL or NK/T-cell Lymphoma
NCT00901147Phase 2Completed
- Sponsor
- Singapore General Hospital
- Start
- Nov 2009
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of panobinostat in peripheral T-cell lymphoma (PTCL), Natural killer T-cell lymphoma (NKTL), sponsored by Singapore General Hospital. Started Nov 2009; status: completed.
02
Drugs
panobinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT00901147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901147.